Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.
Journal: JAMA
Published: July 13, 2026
Estimand Endpoints for Longitudinal Measures of Continuous Disease Progression with an Alzheimer's Disease Example.
Journal: Therapeutic innovation & regulatory science
Published: February 10, 2025
Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: July 23, 2024
Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: July 15, 2024
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
Journal: Neurology
Published: February 22, 2024
Novel avenues of tau research.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 27, 2023
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: June 04, 2021
Donanemab in Early Alzheimer's Disease.
Journal: The New England journal of medicine
Published: March 15, 2021
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: March 15, 2019
Cognitive performance in mid-stage Parkinson's disease: functional connectivity under chronic antiparkinson treatment.
Journal: Brain imaging and behavior
Published: September 25, 2017
Freezing of gait in Parkinson's disease: from pathophysiology to emerging therapies.
Journal: Neurodegenerative disease management
Published: September 08, 2016
Last Updated: 09/26/2026